Latest news
25 items- SECSEC Form DEFM14A filed by Atreca Inc.DEFM14A - Atreca, Inc. (0001532346) (Filer)
- INSIDEROrwin John A bought $0 worth of Series A Junior Preferred Stock (1 units at $0.01) (SEC Form 4)4 - Atreca, Inc. (0001532346) (Issuer)
- SECSEC Form PREM14A filed by Atreca Inc.PREM14A - Atreca, Inc. (0001532346) (Filer)
- INSIDERSerafini Tito sold $1,455 worth of shares (20,788 units at $0.07), decreasing direct ownership by 32% to 43,636 units (SEC Form 4)4 - Atreca, Inc. (0001532346) (Issuer)
- INSIDEROrwin John A sold $8,597 worth of shares (22,951 units at $0.37), decreasing direct ownership by 23% to 77,541 units (SEC Form 4)4 - Atreca, Inc. (0001532346) (Issuer)
- INSIDERSerafini Tito sold $3,144 worth of shares (8,393 units at $0.37), decreasing direct ownership by 12% to 64,424 units (SEC Form 4)4 - Atreca, Inc. (0001532346) (Issuer)
- INSIDERCourtney Phillips sold $2,645 worth of shares (7,061 units at $0.37), decreasing direct ownership by 12% to 50,431 units (SEC Form 4)4 - Atreca, Inc. (0001532346) (Issuer)
- SECSEC Form 15-12G filed by Atreca Inc.15-12G - Atreca, Inc. (0001532346) (Filer)
- SECSEC Form S-8 POS filed by Atreca Inc.S-8 POS - Atreca, Inc. (0001532346) (Filer)
- SECSEC Form S-8 POS filed by Atreca Inc.S-8 POS - Atreca, Inc. (0001532346) (Filer)
- SECSEC Form S-8 POS filed by Atreca Inc.S-8 POS - Atreca, Inc. (0001532346) (Filer)
- SECSEC Form S-8 POS filed by Atreca Inc.S-8 POS - Atreca, Inc. (0001532346) (Filer)
- SECSEC Form S-8 POS filed by Atreca Inc.S-8 POS - Atreca, Inc. (0001532346) (Filer)
- SECSEC Form DEFA14A filed by Atreca Inc.DEFA14A - Atreca, Inc. (0001532346) (Filer)
- SECSEC Form DEFA14A filed by Atreca Inc.DEFA14A - Atreca, Inc. (0001532346) (Filer)
- SECSEC Form EFFECT filed by Atreca Inc.EFFECT - Atreca, Inc. (0001532346) (Filer)
- SECSEC Form EFFECT filed by Atreca Inc.EFFECT - Atreca, Inc. (0001532346) (Filer)
- SECSEC Form POS AM filed by Atreca Inc.POS AM - Atreca, Inc. (0001532346) (Filer)
- SECSEC Form POS AM filed by Atreca Inc.POS AM - Atreca, Inc. (0001532346) (Filer)
- SECSEC Form 25 filed by Atreca Inc.25 - Atreca, Inc. (0001532346) (Filer)
- NEWS12 Health Care Stocks Moving In Friday's Intraday SessionGainers Better Therapeutics (NASDAQ:BTTX) shares increased by 65.4% to $0.06 during Friday's regular session. The market value of their outstanding shares is at $3.1 million. Carmell (NASDAQ:CTCX) shares rose 38.52% to $3.2. The market value of their outstanding shares is at $73.8 million. P3 Health Partners (NASDAQ:PIII) stock rose 38.23% to $0.98. The market value of their outstanding shares is at $112.5 million. Akebia Therapeutics (NASDAQ:AKBA) shares rose 28.1% to $1.75. The market value of their outstanding shares is at $330.6 million. The company's, Q4 earnings came out yesterday. Acrivon Therapeutics (NASDAQ:ACRV) shares increased by 26.03% to $6.39. The market value of their ou
- NEWS12 Health Care Stocks Moving In Monday's After-Market SessionGainers CareMax (NASDAQ:CMAX) stock increased by 16.9% to $8.0 during Monday's after-market session. The market value of their outstanding shares is at $29.9 million. Burning Rock Biotech (NASDAQ:BNR) stock moved upwards by 12.34% to $0.91. The market value of their outstanding shares is at $93.4 million. LifeMD (NASDAQ:LFMD) shares increased by 11.19% to $8.84. The market value of their outstanding shares is at $346.5 million. The company's, Q4 earnings came out today. SCWorx (NASDAQ:WORX) stock increased by 9.13% to $2.03. The market value of their outstanding shares is at $2.4 million. Innate Pharma (NASDAQ:IPHA) shares rose 8.79% to $2.66. The market value of their outstanding share
- SECSEC Form DEFA14A filed by Atreca Inc.DEFA14A - Atreca, Inc. (0001532346) (Filer)
- SECAtreca Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Atreca, Inc. (0001532346) (Filer)
- SECSEC Form DEFM14A filed by Atreca Inc.DEFM14A - Atreca, Inc. (0001532346) (Filer)
BCEL FAQ
7 questionsWhat does Atreca Inc. do?
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of...Where does BCEL stock trade?
Atreca Inc. (BCEL) is listed on NASDAQ.What sector and industry is BCEL in?
Atreca Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Atreca Inc. go public?
Atreca Inc. (BCEL) completed its IPO in 2019.What are analysts saying about BCEL?
Atreca Inc. has had 1 recent analyst action on file. The most recent action was from Stifel: Buy with a $1400.00 price target on 2022-03-04. Recent price targets cluster around $1400.00.What companies are similar to BCEL?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BCEL side-by-side with any of them on Quantisnow.How can I track BCEL on Quantisnow?
Quantisnow aggregates Atreca Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BCEL to receive live email and push alerts on every new disclosure.